ArticleScientific reports2021
Metabolomics-based discrimination of patients with remitted depression from healthy controls using
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Electroconvulsive Treatment for Depression Alters Mitochondrial Serum Metabolites.Biological psychiatry global open science · 2026Article
- Metabolomics biomarkers for precision psychiatry.Frontiers in psychiatry · 2026Review
- Metabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study.Translational psychiatry · 2025Article
- Alterations in serum nudifloramide associated with response to diverse pharmacological treatments in major depressive disorder: a preliminary study.Metabolic brain disease · 2025Article
- DAMPs cross-talk interpretation of MDD mechanisms.Science advances · 2025Review
- Article
- Serum proteomic changes related to residual impairment in remittent depression are associated with immune and inflammatory processes.Scientific reports · 2024Article
- Using an Interpretable Amino Acid-Based Machine Learning Method to Enhance the Diagnosis of Major Depressive Disorder.Journal of clinical medicine · 2024Article
- Small molecule metabolites: discovery of biomarkers and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Metabolomics Based on Peripheral Blood Mononuclear Cells to Dissect the Mechanisms of Chaigui Granules for Treating Depression.ACS omega · 2022Article
- Review
- Serum Colorectal Cancer Biomarkers Unraveled by NMR Metabolomics: Past, Present, and Future.Analytical chemistry · 2022Article
- Applications of machine learning in metabolomics: Disease modeling and classification.Frontiers in genetics · 2022Review
- Integrated network pharmacology and hepatic metabolomics to reveal the mechanism ofFrontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to investigate differences in metabolic profiles between patients with major depressive disorder (MDD) with full remission (FR) and healthy controls (HCs). A total of 119 age-matched MDD patients with FR (n = 47) and HCs (n = 72) were enrolled and randomly split into training and testing sets. A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.